Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors.

Literature DB >> 25949885

Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors.

Abstract

We improved the migration and survival of chimeric antigen receptor (CAR)-modified T cells in solid tumors by combining CAR-T cells with an armed oncolytic virus. Local delivery of the chemokine RANTES and the cytokine IL-15 by the oncolytic virus enhanced the trafficking and persistence of the CAR-T cells, resulting in improved antitumor effects.

Entities: Disease Gene

Keywords: GD2 antigen; IL-15; RANTES; chimeric antigen receptor; oncolytic virus

Year: 2015 PMID： 25949885 PMCID： PMC4404887 DOI： 10.4161/21505594.2014.988098

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

10 in total

Review 1. Recent progress in the battle between oncolytic viruses and tumours.

Authors: Kelley A Parato; Donna Senger; Peter A J Forsyth; John C Bell
Journal: Nat Rev Cancer Date: 2005-12 Impact factor: 60.716

2. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.

Authors: Nobuhiro Nishio; Iulia Diaconu; Hao Liu; Vincenzo Cerullo; Ignazio Caruana; Valentina Hoyos; Lisa Bouchier-Hayes; Barbara Savoldo; Gianpietro Dotti
Journal: Cancer Res Date: 2014-07-24 Impact factor: 12.701

3. Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors: Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal: N Engl J Med Date: 2014-10-16 Impact factor: 91.245

4. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

Authors: Barbara Savoldo; Carlos Almeida Ramos; Enli Liu; Martha P Mims; Michael J Keating; George Carrum; Rammurti T Kamble; Catherine M Bollard; Adrian P Gee; Zhuyong Mei; Hao Liu; Bambi Grilley; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner; Gianpietro Dotti
Journal: J Clin Invest Date: 2011-04-11 Impact factor: 14.808

Review 5. Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors: Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal: Immunol Rev Date: 2014-01 Impact factor: 12.988

6. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

Authors: Laura A Johnson; Richard A Morgan; Mark E Dudley; Lydie Cassard; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Richard M Sherry; John R Wunderlich; Chyi-Chia R Lee; Nicholas P Restifo; Susan L Schwarz; Alexandria P Cogdill; Rachel J Bishop; Hung Kim; Carmen C Brewer; Susan F Rudy; Carter VanWaes; Jeremy L Davis; Aarti Mathur; Robert T Ripley; Debbie A Nathan; Carolyn M Laurencot; Steven A Rosenberg
Journal: Blood Date: 2009-05-18 Impact factor: 22.113

7. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Authors: Jeong Heo; Tony Reid; Leyo Ruo; Caroline J Breitbach; Steven Rose; Mark Bloomston; Mong Cho; Ho Yeong Lim; Hyun Cheol Chung; Chang Won Kim; James Burke; Riccardo Lencioni; Theresa Hickman; Anne Moon; Yeon Sook Lee; Mi Kyeong Kim; Manijeh Daneshmand; Kara Dubois; Lara Longpre; Minhtran Ngo; Cliona Rooney; John C Bell; Byung-Geon Rhee; Richard Patt; Tae-Ho Hwang; David H Kirn
Journal: Nat Med Date: 2013-02-10 Impact factor: 53.440

8. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

Authors: Martin A Pule; Barbara Savoldo; G Doug Myers; Claudia Rossig; Heidi V Russell; Gianpietro Dotti; M Helen Huls; Enli Liu; Adrian P Gee; Zhuyong Mei; Eric Yvon; Heidi L Weiss; Hao Liu; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal: Nat Med Date: 2008-11-02 Impact factor: 53.440

9. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Authors: Renier J Brentjens; Marco L Davila; Isabelle Riviere; Jae Park; Xiuyan Wang; Lindsay G Cowell; Shirley Bartido; Jolanta Stefanski; Clare Taylor; Malgorzata Olszewska; Oriana Borquez-Ojeda; Jinrong Qu; Teresa Wasielewska; Qing He; Yvette Bernal; Ivelise V Rijo; Cyrus Hedvat; Rachel Kobos; Kevin Curran; Peter Steinherz; Joseph Jurcic; Todd Rosenblat; Peter Maslak; Mark Frattini; Michel Sadelain
Journal: Sci Transl Med Date: 2013-03-20 Impact factor: 17.956

10. Remission of disseminated cancer after systemic oncolytic virotherapy.

Authors: Stephen J Russell; Mark J Federspiel; Kah-Whye Peng; Caili Tong; David Dingli; William G Morice; Val Lowe; Michael K O'Connor; Robert A Kyle; Nelson Leung; Francis K Buadi; S Vincent Rajkumar; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri
Journal: Mayo Clin Proc Date: 2014-05-14 Impact factor: 7.616

10 in total

32 in total

Review 1. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Authors: Vishal Jindal; Ena Arora; Sorab Gupta
Journal: Med Oncol Date: 2018-05-05 Impact factor: 3.064

Review 2. Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy.

Authors: Gang Xin; David M Schauder; Ryan Zander; Weiguo Cui
Journal: Immunotherapy Date: 2017-09 Impact factor: 4.196

3. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.

Authors: Paola Bocca; Emma Di Carlo; Ignazio Caruana; Laura Emionite; Michele Cilli; Biagio De Angelis; Concetta Quintarelli; Annalisa Pezzolo; Lizzia Raffaghello; Fabio Morandi; Franco Locatelli; Vito Pistoia; Ignazia Prigione
Journal: Oncoimmunology Date: 2017-10-04 Impact factor: 8.110

Review 4. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.

Authors: Kavitha Gowrishankar; Lucy Birtwistle; Kenneth Micklethwaite
Journal: Mamm Genome Date: 2018-07-09 Impact factor: 2.957

5. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.

Authors: Edmund K Moon; Liang-Chuan S Wang; Kheng Bekdache; Rachel C Lynn; Albert Lo; Stephen H Thorne; Steven M Albelda
Journal: Oncoimmunology Date: 2018-01-09 Impact factor: 8.110

Review 6. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.

Authors: Safa Tahmasebi; Reza Elahi; Abdolreza Esmaeilzadeh
Journal: Stem Cell Rev Rep Date: 2019-10 Impact factor: 5.739

7. Metabolism of Immune Cells in the Tumor Microenvironment.

Authors: Jin G Jung; Anne Le
Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622

8. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.

Authors: Shivani Srivastava; Scott N Furlan; Carla A Jaeger-Ruckstuhl; Megha Sarvothama; Carolina Berger; Kimberly S Smythe; Sarah M Garrison; Jennifer M Specht; Sylvia M Lee; Robert A Amezquita; Valentin Voillet; Vishaka Muhunthan; Sushma Yechan-Gunja; Smitha P S Pillai; Christoph Rader; A McGarry Houghton; Robert H Pierce; Raphael Gottardo; David G Maloney; Stanley R Riddell
Journal: Cancer Cell Date: 2020-12-24 Impact factor: 31.743

Review 9. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.

Authors: Pavlina Chuntova; Frances Chow; Payal B Watchmaker; Mildred Galvez; Amy B Heimberger; Evan W Newell; Aaron Diaz; Ronald A DePinho; Ming O Li; E John Wherry; Duane Mitchell; Masaki Terabe; Derek A Wainwright; Jay A Berzofsky; Christel Herold-Mende; James R Heath; Michael Lim; Kim A Margolin; E Antonio Chiocca; Noriyuki Kasahara; Benjamin M Ellingson; Christine E Brown; Yvonne Chen; Peter E Fecci; David A Reardon; Gavin P Dunn; Linda M Liau; Joseph F Costello; Wolfgang Wick; Timothy Cloughesy; William C Timmer; Patrick Y Wen; Robert M Prins; Michael Platten; Hideho Okada
Journal: Neuro Oncol Date: 2021-03-25 Impact factor: 12.300

10. Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice.

Authors: Shiyun Dai; Yun Lv; Weidong Xu; Yuefeng Yang; Chao Liu; Xiwen Dong; Huan Zhang; Bellur S Prabhakar; Ajay V Maker; Prem Seth; Hua Wang
Journal: Cancer Gene Ther Date: 2020-04-20 Impact factor: 5.987